Deficiency or dysfunction of the pulmonary surfactant plays a critical role in the pathogenesis of respiratory diseases of the newborn. After a short review of the pulmonary surfactant, including its role in selected neonatal respiratory conditions, we describe a series of studies conducted by applying two recently developed methods to measure surfactant kinetics. In the first set of studies, namely 'endogenous studies', which used stable isotope-labeled intravenous surfactant precursors, we have shown the feasibility of measuring surfactant synthesis and kinetics in infants using several metabolic precursors, including plasma glucose, plasma fatty acids and body water. In the second set of studies, namely 'exogenous studies', which used a stable isotope-labeled phosphatidylcholine (PC) tracer given endotracheally, we estimated the surfactant disaturated phosphatidylcholine (DSPC) pool size and half-life. The major findings of our studies are presented here and can be summarized as follows: (a) the de novo synthesis and turnover rates of the surfactant (DSPC) in preterm infants with respiratory distress syndrome (RDS) are very low with either precursor; (b) in preterm infants with RDS, pool size is very small and half-life much longer than what has been reported in animal studies; (c) patients recovering from RDS who required higher continuous positive airway pressure pressure after extubation or reintubation have a lower level of intrapulmonary surfactant than those who did well after extubation; (d) term newborn infants with pneumonia have greatly accelerated surfactant catabolism; and (e) infants with uncomplicated congenital diaphragmatic hernia (CDH) and on conventional mechanical ventilation have normal surfactant synthesis, but those requiring extracorporeal membrane oxygenated (ECMO) do not. Information obtained from these studies in infants will help to better tailor exogenous surfactant treatment in neonatal lung diseases.
Introduction
In 1959, Avery and Mead 1 showed that pulmonary surfactant deficiency is a major factor in the pathophysiology of respiratory distress syndrome (RDS). In 1980, Fujiwara et al. 2 administered an exogenous surfactant successfully to preterm infants with RDS for the first time. This was followed by numerous clinical trials that showed a marked reduction in death rates and pneumothorax, and this is now a standard of care. Data suggesting that a disturbed surfactant metabolism has a role in several other neonatal lung diseases, such as congenital diaphragmatic hernia (CDH), meconium aspiration syndrome (MAS), pneumonia and surfactant protein-B (SP-B) deficiency, are accumulating. Surfactant therapy may have a therapeutic role in the management of these clinical conditions.
Surfactant function and composition
The primary function of the surfactant is to decrease the surface tension at the air-liquid interface in the alveoli and distal bronchioles, to promote lung expansion during inspiration and to prevent alveolar collapse at end expiration. Apart from these biophysical properties, the surfactant also plays an important role in pulmonary host defense. 3 A surfactant is a complex mixture of lipids (E90%) and proteins (E10%), which is strikingly comparable across various species, including humans. 4 Of the surfactant lipids, 80 to 90% are phospholipids, of which phosphatidylcholine (PC) is quantitatively the most important, accounting for 70 to 80% of the total. Other lipids include phosphatidylglycerol (PG), phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, sphingomyelin, cholesterol, triacylglycerols and free fatty acids. Approximately 60% of the PC contains two saturated fatty acids (surfactant disaturated phosphatidylcholine or DSPC), of which dipalmitoyl (16:0/16:0; DPPC) is the most abundant. DPPC is the principal surface tension-lowering component of pulmonary surfactant.
Four surfactant proteins (SP) have so far been identified. 5 SP-A and SP-D are hydrophilic, and SP-B and SP-C are hydrophobic.
They are either exclusively lung associated or predominately found in the lung. SP-A is the most abundant surfactant protein and is essential for the formation of tubular myelin. It functions as a regulator of phospholipid insertion into the monolayer, and modulates the uptake and secretion of phospholipids by type II cells. However, mice that lack SP-A indeed have no tubular myelin but have normal lung function and surfactant metabolism even during exercise. 6 Furthermore, together with SP-D, SP-A has an important role in lung defense. 7 SP-A and -D bind pathogens and facilitate their clearance. 7 The absence of SP-D results in increased surfactant lipid pools in the airspaces and emphysema in the lungs of mice.
8 SP-B plays a role in formation of tubular myelin and, together with SP-C, it promotes rapid phospholipid insertion into the air-liquid interface. SP-B also influences the molecular ordering of the phospholipid layer. Infants with a genetic absence of SP-B develop lethal respiratory distress after birth, which can be treated only by lung transplantation. 9 Absence of SP-B causes a loss of lamellar bodies, tubular myelin and an incompletely processed SP-C. 10 SP-C regulates the phospholipid ordering in the monolayer, enhances the reuptake of surfactant lipids in vitro and may have a role in surfactant catabolism. Mice that lack SP-C have normal surfactant and lung function, and have no abnormalities in SP-B processing. 11 However, the stability of the surfactant at low lung volumes is decreased.
Interestingly, the alveolar pool of a surfactant in newborn infants with RDS does not differ much from the alveolar pool of adults without respiratory disease. 12 However, without surfactant supplementation, newborns with RDS develop severe respiratory failure, possibly through a combination of mechanisms, including altered surfactant composition, structural lung immaturity and increased surfactant inactivation. 13 Limited information is available on the role of surfactant proteins in newborn infants with respiratory conditions. Surfactant synthesis, secretion and clearance Surfactant PC is synthesized from phospholipid precursors (for example, fatty acids, glycerol, choline, glucose) in the Golgi apparatus.
14 In the fetal type II cell, intracellular glycogen stores seem to be a major source of the glycerol backbone of PC, whereas in the adult lung glucose from the circulation is a major substrate. Choline is mainly derived from the diet. The fatty acids of surfactant phospholipids are synthesized de novo in the type II cell, or taken up from the blood, or are derived from recycling of alveolar surfactant phospholipids.
14 Lamellar bodies are condensed, highly structured lipoprotein packages that serve as the intracellular storage form of surfactant. Lamellar bodies are secreted into the alveolar space by fusing their limiting membrane with the plasma membrane. After secretion, the lamellar bodies unravel to form loose membranous arrays and lattice-like structures, the tubular myelin. At alveolar surface expansion during inspiration, surfactant components are inserted from the hypophase (epithelial lining fluid (ELF)) into the monolayer. At expiration the alveolar surface reduces and the monolayer is compressed, thereby squeezing out some surfactant proteins, unsaturated PC and other lipids. By this mechanism, the monolayer comprises mainly DPPC, which is the most important surface-tension-lowering component during compression.
The alveolar surfactant can be cleared by different pathways. Surfactant components can be reutilized through uptake by the type II cell, incorporation into the lamellar bodies and then direct re-secretion. 15 Another way is recycling of degraded surfactant components to synthesize new surfactant lipids or proteins. Finally, the surfactant can be removed from the lung, either as intact molecules or as degraded products. 16 The efficiency of recycling is age dependent, and has been calculated to be 90% in young pigs, 17 >90% in newborn rabbits and 50% in adult rabbits. 18 
Surfactant kinetics
The time required for de novo PC synthesis, secretion and significant alveolar accumulation has been studied in animals using radioactively labeled substrates. 19 Compared with adult animals, the time to reach peak specific activity is longer in term newborns. 20 Preterm ventilated lambs show a slow movement of surfactant PC from the synthesis sites to the alveolus, similar to term ventilated lambs. 21 Recently, stable isotope techniques were used to study surfactant metabolism in human infants. Labeled precursors were infused intravenously and incorporation of label was measured by mass spectrometry in surfactant PC or DSPC isolated from tracheal aspirates. In preterm infants with RDS who received a 24-h intravenous infusion of the stable isotope [U- 13 C]glucose, the palmitic acid of surfactant PC became labeled at approximately 17 h and was maximally labeled after E75 h. 22, 23 By using other precursors such as [U- 13 C]palmitic acid, [U- 13 C]linoleic acid and [1-13 C]acetate to study surfactant kinetics, similar results were obtained. 24, 25 In term ventilated neonates without significant lung disease using infusion of [U- 13 C]glucose, [U-13 C]palmitic acid or [1-13 C]acetate as precursor, the first appearance of label in surfactant PC was after E9 h from the start of the infusion, and the maximal enrichment at E44 h. [25] [26] [27] As in animal studies, these results of human stable isotope studies show slower surfactant kinetics in preterm infants compared with term infants. The kind of precursor does not affect the results. The fractional synthesis rate (FSR) of surfactant after infusion of labeled glucose is a measure of the percentage of surfactant that is synthesized from glucose per day. In premature infants who received a 24-h [U-13C ]glucose infusion, the FSR was calculated to be E4% day -1 . 22,23 Different values were found for different precursors: pre-term infants who received labeled palmitic acid and linoleic acid had an FSR of E12 and E25% day -1 , respectively. 24 FSR in preterm and term infants after infusion of labeled acetate was E2 and E15% day -1 , respectively. 23 When term infants received labeled palmitic acid, the FSR was found to be E17% day -1 . 26 After infusion with labeled glucose, term infants had a FSR of E8% day -1 . 27 These data show a lower FSR in preterm infants compared with term infants.
The slow secretion and alveolar accumulation of surfactant is balanced in the term and preterm lungs by slow catabolism and clearance. For example, the half-life of radiolabeled surfactant phospholipids given endotracheally to term lambs is about 6 days. 28 However, in premature baboons, using the same method the half-life is about 30 h, 29 which may be because of more recycling in premature animals, and because of a species difference. Half-lives calculated in animal studies differ depending on gestational age, postnatal age, the labeled substrate used and the surfactant pool studied.
Half-life measurements of labeled surfactant in human infants have been carried out mainly in preterm infants with RDS. Halflives were longer when measured after the intravenous use of labeled precursors: the half-life of 13 C-labeled PC-palmitate measured in tracheal aspirates of preterm infants with RDS after labeled glucose infusion was E96 h. 22, 23, 30 In preterm infants the surfactant half-life after infusion of [U- 13 [25] [26] [27] Thus, surfactant half-life is different between pre-term and term infants, with a lower disappearance of label in the preterm infants reflecting slower surfactant kinetics, especially in RDS.
There are two studies in critically ill term infants that used different metabolic precursors for surfactant metabolism. 25, 31 Cogo et al., after infusing labeled fatty acids in a group of critically ill infants with various diagnoses, showed marked patient differences in PC kinetics. 31 Bohlin et al. reported that term infants with primary respiratory failure had a surfactant metabolism similar to that in preterm infants with RDS, suggesting either delayed maturity of the surfactant system or disruption from the underlying disease. 25 In summary, animal studies show a slower surfactant turnover in newborns compared with adults. In human studies using stable isotopes, the surfactant PC metabolism is even slower in preterm infants with RDS compared with term infants without lung disease. Moreover, term infants with respiratory failure have abnormal surfactant metabolism, which resembles that of preterm infants with RDS.
Surfactant pool size
In most species studied, PC and especially DSPC, increase in the last trimester of pregnancy. 32 In amniotic fluid, surfactant concentrations increase, reflecting accumulation of alveolar surfactant. This increase is also reflected in an increasing lecithin/ sphingomyelin (L/S) ratio. 33 During and shortly after birth, large amounts of surfactant are released into the alveolar space. 34 As there is no depletion of the intracellular surfactant pool, this increase in alveolar pool shortly after birth is accompanied by an increase in de novo surfactant synthesis. However, incorporation studies, as mentioned above, showed slow surfactant metabolism, which implies that it takes a long time before de novo synthesized surfactant is detected in the alveolar space. Increased lung tissue and alveolar surfactant pools can only be explained by the rapid mobilization of surfactant from other pools (lamellar bodies and small vesicles) within type II cells. The amount of lung tissue and alveolar surfactant changes with age. Surfactant pools are very large in the newborn period in all species studied to date and decrease subsequently with lung maturity. In humans, total amounts of saturated PC in alveolar washes at autopsy also decrease with age. 12 In preterm infants with RDS, surfactant pool sizes in the alveolus are low (2 to 10 mg kg -1 ). 20 Total lung DSPC in the human adult, at autopsy, was E22 mg kg -1 , and that in alveolar wash was E2 mg kg -1 . 12 In human infants surfactant pool size can be estimated in vivo by measuring the dilution of a labeled surfactant component. Hallman et al. 35 and Griese et al. 36 showed an apparent phospholipid pool size of E16 mg kg -1 in human preterm neonates with RDS, by using PG as label to measure surfactant pool size. Pool size measurements in preterm infants with RDS using endotracheally administered stable isotope ( 13 C-DPPC) in combination with a treatment dose of surfactant (100 mg kg -1 ) showed an endogenous surfactant PC pool size (before treatment) ranging from 1 to 15 mg kg -1 , 37 whereas term infants without RDS have three or more times that value. 38 As synthetic rates of surfactant in preterm infants are low, it is clear that pulmonary surfactant can only be rapidly increased by surfactant replacement therapy.
Effects of surfactant therapy on surfactant synthesis in preterm infants with RDS Although the administration of exogenous surfactant has become the routine treatment of RDS in the preterm infant, there is very little information regarding the effects of exogenous surfactant on endogenous surfactant metabolism. In healthy adult rabbits in vivo, administration of surfactant to the left lung only resulted in increased incorporation of palmitic acid from the plasma into the surfactant PC in the left lung but not in the right lung, 39 suggesting stimulation of endogenous synthesis. In preterm ventilated lambs, surfactant treatment stimulated [ 3 H]palmitic acid incorporation into surfactant PC after correction for the increased surfactant pool. 40 However, in 3-day-old rabbits, administration of surfactant did not influence the incorporation of labeled precursor in the total lung surfactant pool. 41 In preterm infants with RDS, the half-life of PG was independent of the dose of exogenous surfactant (60 vs 120 mg kg -1 ). 35 This indicates that the absolute turnover had doubled after two doses of surfactant compared with that after one dose. More recent work with stable isotopes in infants shows that the incorporation of 13 C from intravenous [U- 13 C]glucose into alveolar surfactant PC palmitate increased after exogenous surfactant treatment. 30 In summary, there is little information from animal and human studies on the effect of exogenous surfactant therapy on surfactant metabolism.
Effects of prenatal corticosteroids on surfactant synthesis in preterm infants with RDS In many in vitro studies corticosteroids have been found to increase the activity of the enzymes involved in surfactant PC synthesis [42] [43] [44] [45] [46] and also increase surfactant protein synthesis. 44 In in vitro experiments with lung slices and isolated type II cells, corticosteroids were found to increase the incorporation of radiolabel precursors into surfactant PC, reflecting increased PC synthesis. 43, 46, 47 Prenatal corticosteroid treatment in preterm lambs rapidly increases surfactant protein mRNAs and surfactant proteins in lung tissue. 48 In a study by Kessler et al. 49 in premature baboons, a 72-h treatment with prenatal dexamethasone did not increase radioactive palmitate incorporation in lung lipids, but increased total lung phospholipids and alveolar lavage DPPC in lung lavage fluid at birth. Bunt et al. 50 used stable isotope-labeled glucose in preterm baboons to measure the synthesis rate of surfactant PC from plasma glucose. The synthesis was doubled after a 48-h treatment with prenatal corticosteroids. In preterm infants it was also found that two doses of prenatal corticosteroids doubled the endogenous surfactant synthesis from plasma [U-
13 C]glucose. 51 In summary, prenatal corticosteroids enhance surfactant PC synthesis in vivo, but de novo synthesis rates remain low, and alveolar pool sizes are not increased within 48 h. In preterm animals with RDS, prenatal corticosteroids improve pulmonary compliance within 15 h, 52 accompanied by stimulated structural development. [53] [54] [55] [56] [57] [58] Therefore, the pathophysiology of the improved lung function after prenatal corticosteroids remains controversial.
Surfactant status of preterm infants recovering from RDS
The common belief that after surfactant replacement the exogenous surfactant is fully retained by the lung of the preterm infants suffering from RDS has been recently challenged by Verlato et al., 59 who studied whether reduced amounts of pulmonary surfactant contribute to post-extubation respiratory failure in preterm infants who had RDS, needed mechanical ventilation and exogenous surfactant replacement for treatment of moderate/severe RDS and could not be extubated before day 3 of life. Verlato et al. studied 88 preterms by the 'exogenous' tracing approach. They administered endotracheally 13 C-DPPC as tracer before extubation, for the estimation of surfactant DSPC pool size and half-life. Patients were retrospectively divided into three groups: (a) extubation failure if, after extubation, they needed reintubation or a high-setting continuous positive airway pressure (X6 cm H 2 O of continuous positive airway pressure and a fraction of inspired oxygen >0.4), (b) extubation success if they did not meet the failure criteria and (c) not extubated if they needed ongoing ventilation. Sixteen, 23 and 24 neonates were categorized in the extubation failure, extubation success and not extubated groups, respectively. The mean DSPC pool size was smaller in the extubation failure group than in the extubation success group (25 vs 43 mg kg -1 ), and it was 37 mg kg -1 in the not extubated group. The mean DSPC half-life was 19, 24 and 28 h in the extubation failure, extubation success and not extubated groups, respectively. The authors concluded that marginal surfactant deficiency may contributed to extubation failures or to the need for high continuous positive airway pressure settings after extubation. Perhaps more importantly, the authors draw the attention on individual differences in exogenous surfactant handling or on individual differences in endogenous synthesis. Interestingly, a recent report in abstract form showed that the administration of exogenous surfactant (Infasurf 3 ml kg -1 ) in infants below 28 weeks of gestation and beyond 7 days of age resulted in an improvement in respiratory severity score. 60 Neonatal pneumonia Pneumonia in children and newborn infants may be associated with surfactant dysfunction and acute RDS. [61] [62] [63] [64] [65] [66] There are studies involving a small number of neonates who have been treated with rescue surfactant replacement for sepsis and pneumonia that have shown improved gas exchange compared with no surfactant treatment. 61,63,64,67 -69 Verlato et al. 70 used the 'exogenous' tracing approach with an endotracheal administration of 13 C-labeled DPPC to study surfactant kinetics in full term with pneumonia, and in preterms with RDS. In this small study the authors found that the amount of DSPC recovered from the tracheal aspirates was not different among the study groups, whereas its half-life was significantly shorter in infants with pneumonia (19.3 ± 7.3 h) than in preterms with RDS (28.7±15.9 h). The mean half-life of term control infants with normal lungs was 62 h.
Conclusion
If it is apparent from one side that large randomized controlled studies are necessary to evaluate the effects of surfactant treatment on morbidity and mortality, it may well be that the dose and time intervals of exogenous surfactant therapy ought to be different in patients with neonatal pneumonia from the patients with RDS.
MAS
Aspiration of meconium into the lungs directly inhibits surfactant function and induces an inflammatory response in the lung with possible detrimental effects on type II cell function, and thereby surfactant metabolism. Surfactant function is inhibited by meconium in a concentration-dependent way. 71, 72 Meconium increases the minimum and maximum surface tensions and lowers the surface-spreading rate of surfactant. [71] [72] [73] Studies of surfactant concentrations and composition in MAS are scarce. Cleary et al. 74 found decreased SP-A and SP-B levels in the large aggregates of surfactant in a rat model of MAS. However, phospholipid and DPPC levels did not change significantly after meconium instillation in either lung tissue or bronchoalveolar lavage fluid (BAL). Analyses of BAL fluid from eight ventilated infants with MAS showed no difference in phospholipid and SP-A content compared with control subjects. 75 However, concentrations of non-surfactant protein and albumin were more than three times those found in normal lung. In MAS infants who required extracorporeal membrane oxygenation (ECMO), surfactant phospholipids, PC and SP-A in tracheal aspirates increased during the ECMO treatment. 76, 77 One study investigated the surfactant kinetics in the presence of meconium. 78 This in vitro study in type II cells of adult rats showed that meconium in low concentrations (1%) increases the PC secretion by type II cells, but had no effect on surfactant PC synthesis. Higher meconium concentrations were toxic to cultured type II cells, though the effect of these higher concentrations on surfactant synthesis is not known. Janssen et al. 27 studied surfactant metabolism in MAS infants on ECMO with the 'endogenous approach' using [U- 13 C]glucose as a precursor for surfactant PC palmitate. The FSR in MAS infants was E3.3% day À1 (compared with controls 8% day -1 , P ¼ 0.058) and peak enrichment was significantly lower than in controls P ¼ 0.027), suggesting lower synthesis in MAS. PC concentration in ELF in MAS was E4 mg ml -1 (significantly lower than controls: 12.8 mg ml -1 ). The half-life of endogenous surfactant was 69 h (not different from controls). With endotracheally administered 2 H 3 -DPPC as label, surfactant pool PC size was measured to be E50 mg kg -1 in neonates with MAS requiring ECMO, which was not significantly different from controls or other ECMO infants with persistent pulmonary hypertension of the newborn. 79 Exogenous administration of surfactant in animal models of MAS improves lung function and morphology, especially when the surfactant is given at a high dose (200 mg kg -1 ). 80 Several studies showed an improvement in oxygenation after surfactant therapy, although most infants required two or more doses of exogenous surfactant. 81 In a randomized trial, three doses of bovine surfactant (150 mg kg -1 ) were administered to 20 infants with MAS. Infants treated with surfactant had improved oxygenation, a reduction in severity of pulmonary morbidity, a decrease in ECMO requirement and a decrease in hospitalization time compared with the control group (n ¼ 20). 82 Lotze et al. 83 carried out a trial in term infants with severe respiratory distress who received four doses of bovine surfactant (100 mg kg -1 dose -1 ) at E30 h after birth. Half of these infants had MAS. They were unable to show a difference in oxygenation, pulmonary morbidity, or hospitalization, although the need for ECMO in the surfactanttreated group was decreased. From these studies it seems that surfactant therapy in MAS is most effective when given in the early phase of respiratory failure, and at a high dose. Lavage with surfactant could remove meconium, inflammatory cells, edema fluid, proteins and other debris from the lungs, leaving behind a layer of functional exogenous surfactant. 84 Animal studies showed a beneficial effect from surfactant lavage on pulmonary function, radiographical and histological appearance. There are few reports of lavage therapy in human neonates with MAS. 85 However, the patient groups were small and no control group was included. Recently, a multicenter, randomized controlled trial comparing surfactant lavage with standard treatment of MAS has been reported. 86 A trend towards shorter duration of ventilation and improvement in oxygenation were noted, but the differences were not statistically significant.
In conclusion, surfactant inactivation seems to play a more important role in the pathophysiology of MAS than surfactant deficiency. In the sickest MAS infants on ECMO, surfactant synthesis is disturbed. Surfactant therapy seems to be effective in MAS, and should probably be given at a high dose and at an early stage in the development of the disease.
CDH
Although CDH lungs are immature and show morphologically some resemblance to lungs of preterm infants with RDS, it is still unclear whether a primary surfactant deficiency is present in human CDH. Several animal models have been developed to study the pathogenesis of CDH. In bronchoalveolar lavage (BAL) fluid of surgically created CDH lambs, the amounts of phospholipids, PC, SP-A and SP-B are decreased compared with controls. 87, 88 However, the amniotic L/S ratio is not different in CDH lambs compared with control lambs. 88 In vitro studies in isolated type II cells of CDH lambs show a decreased incorporation of choline into PC, 87 suggesting decreased surfactant synthesis in CDH. Human studies show contradictory results; the L/S ratios in amniotic fluid have been reported to be either decreased or normal. 89 SP-A and DSPC concentrations in amniotic fluid were lower in fetuses with CDH who died or required ECMO. 90 Autopsy studies in CDH infants who died at birth or within the first few days of life showed decreased SP-A in lung tissue. 91 No difference in L/S ratio, PC and PG concentrations in BAL fluid from CDH infants was found compared with age-matched controls. 92 Cogo et al. has recently conducted a series of studies tracing pulmonary surfactant in ventilated CDH newborn infants with stable isotopes. In the first study using the 'endogenous approach', surfactant DSPC synthesis and metabolism were compared between CDH patients and control subjects. Secretion time was 8.3 ± 5.5 and 8.5±2.5 h and peak time 51.9±15.2 and 51±13 h in infants with CDH and in control subjects, respectively. FSR was not different for infants with CDH and control subjects (P ¼ 0.4). It was concluded that surfactant DSPC synthesis and kinetics were not significantly deranged in infants with CDH compared with control subjects, and speculated that factors other than surfactant deficiency, such as lower surface area or increased DSPC catabolism, may have contributed to surfactant pool alteration in CDH. 26 In a second study, Cogo PE et al. 38 studied surfactant DSPC half-life, turnover and apparent pool size in CDH newborns with no ECMO by the 'exogenous tracing approach'. In 13 CDH infants DSPC half-life was shorter (24 vs 53 h), turnover was faster (0.6 vs 1.5 d À1 ), apparent pool size smaller (34 and 57 mg kg -1 body weight) and DSPC amount from tracheal aspirates lower (2.4 and 4.6 mg ml À1 epithelial lining fluid (ELF)) than in controls. The data from the 'exogenous tracer' suggested that surfactant kinetics was grossly abnormal in mechanically ventilated CDH. This study could not ascertain whether alterations of DSPC kinetics in CDH infants were caused by a primary surfactant deficiency or were secondary to oxygen therapy and ventilator support. In the third study of this series Cogo et al. 93 developed a new approach to measure DSPC net synthesis and kinetics by using a dual stable isotope tracer approach, that is, combining the 'endogenous' and 'exogenous' techniques in the same patient. All infants received simultaneously an intratracheal (carbon-13 DPPC) and an intravenous (deuterated palmitic acid) stable isotope tracer. DSPC net synthesis from plasma palmitate was nearly identical in infants with CDH and control subjects (8.6 and 8.1 mg kg -1 d -1 ). DSPC apparent pool size was 36.7 ± 7.5 and 58.5±9.1 mg kg -1 , P ¼ 0.07 and half-life was 26 and 50, P ¼ 0.03 in infants with CDH and control subjects, respectively. Both DSPC turnover and percentage of catabolism/recycling significantly correlated with duration of mechanical ventilation. In summary, this study confirmed that (1) synthesis was not reduced in ventilator-dependant CDH patients; (2) that DSPC turnover was faster, presumably reflecting an increased DSPC catabolism/ recycling; and speculates that (3) increased catabolism may ultimately lead to a secondary surfactant deficiency.
When patients with CDH were studied on ECMO by the 'exogenous' tracer 79 surfactant PC pool size was comparable in CDH infants and in term newborn with severe respiratory failure who were not on ECMO (73 vs 69 mg kg -1 , respectively). In CDH infants on ECMO, Janssen 27 measured FSR by using [U- 13 C]glucose as a precursor and found it to be lower than in controls (2.4 vs 8% day -1 ) with a similar half-life of endogenous surfactant of E 65 h. It is unclear at present if these discrepancies in pool sizes and synthesis were because of ECMO or the severity of the patients studied. There are only a few reports of surfactant treatment in human CDH infants. [94] [95] [96] Bos et al. 94 showed an improvement of oxygenation in three of five infants with CDH after surfactant administration. When the surfactant was given prophylactically to high-risk neonates with CDH, all three infants survived. 95 Surfactant treatment in nine infants with CDH who required ECMO had no beneficial effect on lung function, morbidity or survival. 96 Recent studies on surfactant supplementation in CDH 97 show no benefit associated with surfactant therapy for term infants with a prenatal diagnosis of isolated CDH and a lower survival rate in CDH preterm infants treated with surfactant therapy. 98 Even today it is still not clear whether there is a primary surfactant deficiency in CDH. We suggest that there is inactivation of surfactant function because of the intensive ventilation, 99 which is often necessary in CDH infants, although a decreased surfactant synthesis because of severe hypoplasia of the lungs (especially in the more severe cases of CDH) cannot however be excluded.
Conclusions
We reviewed the role of surfactant on selected respiratory condition of the preterm and term newborn infants with emphasis on human studies and more specifically on the recent studies based on stable isotopes. These studies have produced novel information on surfactant kinetics in vivo in infants who require endotracheal intubation. This novel information is and will be proven to be very valuable to answer clinical questions regarding pulmonary surfactant in humans.
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